Compare CSBR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | PLRX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.0M | 74.9M |
| IPO Year | 2015 | 2020 |
| Metric | CSBR | PLRX |
|---|---|---|
| Price | $5.63 | $1.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 7.2K | ★ 526.9K |
| Earning Date | 03-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,900,000.00 | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $1.09 |
| 52 Week High | $9.63 | $1.95 |
| Indicator | CSBR | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 38.90 |
| Support Level | $5.50 | $1.14 |
| Resistance Level | $6.31 | $1.37 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 3.63 | 6.90 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.